Theranostics of Neuroendocrine Tumors | Zendy

Sze Ting Lee | Zendy; Harshad Kulkarni | Zendy; Aviral Singh | Zendy; Richard P. Baum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Theranostics of Neuroendocrine Tumors

Author(s) -

Sze Ting Lee,

Harshad Kulkarni,

Aviral Singh,

Richard P. Baum

Publication year - 2017

Publication title -

visceral medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.598

H-Index - 17

eISSN - 2297-475X

pISSN - 2297-4725

DOI - 10.1159/000480383

Subject(s) - radionuclide therapy , neuroendocrine tumors , somatostatin receptor , somatostatin , medicine , peptide receptor , positron emission tomography , quality of life (healthcare) , oncology , toxicity , nuclear medicine , receptor , nursing

Somatostatin receptor positron emission tomography/computed tomography using 68 Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research